{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:14:47Z","timestamp":1788491687894,"version":"build-2803163510"},"reference-count":74,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Scientific Research Fund of the National Health and Wellness Commission - Major Science and Technology Plan Project for Health and Wellness in Zhejiang Province","award":["WKJ-ZJ-2401"],"award-info":[{"award-number":["WKJ-ZJ-2401"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Biochemical recurrence (BCR) after radical prostatectomy (RP) remains a major clinical challenge. Although metabolic reprogramming drives prostate cancer (PCa) progression, its predictive value for BCR and its interplay with the tumor immune microenvironment (TIME) remain incompletely understood. By integrating weighted gene co-expression network analysis (WGCNA) with machine learning, we identified four metabolic-related hub genes (GDPD1, PLA2G7, PTGDS, and SRD5A2) and developed an XGBoost-Cox model that accurately stratified BCR risk (training 5-year AUC: 0.858; validation 5-year AUC: 0.745). SHAP analysis enhanced the model\u2019s interpretability, while immunohistochemistry (IHC) validated differential protein expression of these targets across 32 clinical specimens. Furthermore, immune profiling demonstrated that these genes are closely linked to M2 macrophage-mediated immunosuppression and altered T-cell infiltration. To translate these biomarkers into therapeutic targets, we employed in silico screening, molecular docking, and molecular dynamics simulations, identifying (-)-epigallocatechin gallate (EGCG) as a promising multi-target candidate. Subsequent in vitro assays confirmed that EGCG binds stably to GDPD1, PTGDS, and SRD5A2, effectively suppressing malignant PCa phenotypes and prostate-specific antigen (PSA) secretion. In summary, we established a robust and interpretable model for predicting BCR after RP, and our in vitro validation suggests that EGCG holds promise as a therapeutic agent to delay PCa progression.<\/jats:p>","DOI":"10.3390\/ijms27114797","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:17:58Z","timestamp":1779812278000},"page":"4797","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Metabolic-Related Gene Signature for Predicting Biochemical Recurrence After Radical Prostatectomy: An Integrative Analysis and Targeted Therapeutic Validation"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1379-6040","authenticated-orcid":false,"given":"Wankun","family":"Wang","sequence":"first","affiliation":[{"name":"School of Medicine, Zhejiang University, Hangzhou 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2807-323X","authenticated-orcid":false,"given":"Xiujuan","family":"Hong","sequence":"additional","affiliation":[{"name":"School of Medicine, Zhejiang University, Hangzhou 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Medicine, Zhejiang University, Hangzhou 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganpei","family":"Jiao","sequence":"additional","affiliation":[{"name":"School of Medicine, Zhejiang University, Hangzhou 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Cai","sequence":"additional","affiliation":[{"name":"Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Medicine, Zhejiang University, Hangzhou 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2059-7142","authenticated-orcid":false,"given":"Zhibing","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Medicine, Zhejiang University, Hangzhou 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Medicine, Zhejiang University, Hangzhou 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review","volume":"75","author":"Arfi","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000481438","article-title":"Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review","volume":"100","author":"Artibani","year":"2018","journal-title":"Urol. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","article-title":"Biochemical recurrence in patients with prostate cancer after primary definitive therapy: Treatment based on risk stratification","volume":"27","author":"Shore","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1464-410X.2011.10422.x","article-title":"The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: Long-term follow-up","volume":"109","author":"Antonarakis","year":"2012","journal-title":"BJU Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41746-025-01930-6","article-title":"Integrative machine learning models predict prostate cancer diagnosis and biochemical recurrence risk: Advancing precision oncology","volume":"8","author":"Wang","year":"2025","journal-title":"NPJ Digit. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Sato, K., Sakamoto, S., Saito, S., Shibata, H., Yamada, Y., Takeuchi, N., Goto, Y., Tomokazu, S., Imamura, Y., and Ichikawa, T. (2024). Time-dependent personalized prognostic analysis by machine learning in biochemical recurrence after radical prostatectomy: A retrospective cohort study. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-13203-8"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zhang, T., Ide, H., Lu, J., Lu, Y., China, T., Nagata, M., Hachiya, T., and Horie, S. (2025). Predicting Biochemical Recurrence After Robot-Assisted Prostatectomy with Interpretable Machine Learning Model. J. Clin. Med., 14.","DOI":"10.3390\/jcm14197079"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101272","DOI":"10.1016\/j.neo.2026.101272","article-title":"Cell type composition in bulk prostate cancer tissue is a prognostic biomarker","volume":"72","author":"Zhang","year":"2026","journal-title":"Neoplasia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/s41416-024-02761-0","article-title":"An 18-gene signature of recurrence-associated endothelial cells predicts tumor progression and castration resistance in prostate cancer","volume":"131","author":"Lin","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The Emerging Hallmarks of Cancer Metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ajur.2019.12.003","article-title":"Lipogenic effects of androgen signaling in normal and malignant prostate","volume":"7","author":"Mah","year":"2020","journal-title":"Asian J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1158\/0008-5472.CAN-21-1392","article-title":"Fatty Acid Synthesis in Prostate Cancer: Vulnerability or Epiphenomenon?","volume":"81","author":"Sena","year":"2021","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41585-020-0288-x","article-title":"Tumour metabolism and its unique properties in prostate adenocarcinoma","volume":"17","author":"Bader","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41577-024-01026-4","article-title":"Cancer cell metabolism and antitumour immunity","volume":"24","author":"Rathmell","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e148549","DOI":"10.1172\/JCI148549","article-title":"Fighting in a wasteland: Deleterious metabolites and antitumor immunity","volume":"132","author":"Watson","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2019.01.048","article-title":"Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes","volume":"76","author":"Preisser","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.euf.2017.02.017","article-title":"Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review","volume":"4","author":"Lamy","year":"2018","journal-title":"Eur. Urol. Focus"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Xie, Y., Ella, K.M., Gibbs, T.C., Yohannan, M.E., Knoepp, S.M., Balijepalli, P., Meier, G.P., and Meier, K.E. (2024). Characterization of Lysophospholipase D Activity in Mammalian Cell Membranes. Cells, 13.","DOI":"10.3390\/cells13060520"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrc3162","article-title":"Choline metabolism in malignant transformation","volume":"11","author":"Glunde","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/09687680802537605","article-title":"Isolation, characterization and molecular 3D model of human GDE4, a novel membrane protein containing glycerophosphodiester phosphodiesterase domain","volume":"25","author":"Chang","year":"2008","journal-title":"Mol. Membr. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3892\/ijo.2025.5793","article-title":"Lp-PLA2 in the cancer landscape: From molecular mechanisms to therapeutic potential (Review)","volume":"67","author":"Yang","year":"2025","journal-title":"Int. J. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.18632\/oncotarget.397","article-title":"Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins","volume":"2","author":"Vainio","year":"2011","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"21680","DOI":"10.1038\/s41598-024-72985-w","article-title":"Leveraging cell death patterns to predict metastasis in prostate adenocarcinoma and targeting PTGDS for tumor suppression","volume":"14","author":"Chen","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/path.4993","article-title":"Lipocalin-type prostaglandin D synthase-derived PGD(2) attenuates malignant properties of tumor endothelial cells","volume":"244","author":"Omori","year":"2018","journal-title":"J. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ijc.26414","article-title":"A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease","volume":"131","author":"Thompson","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1002\/ctm2.581","article-title":"Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype","volume":"12","author":"Boibessot","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"22344","DOI":"10.1074\/jbc.M109.018341","article-title":"Structural basis of the catalytic mechanism operating in open-closed conformers of lipocalin type prostaglandin D synthase","volume":"284","author":"Kumasaka","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jb\/mvg006","article-title":"Cloning, expression, crystallization, and preliminary X-ray analysis of recombinant mouse lipocalin-type prostaglandin D synthase, a somnogen-producing enzyme","volume":"133","author":"Irikura","year":"2003","journal-title":"J. Biochem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41585-025-01112-9","article-title":"SRD5A2 and emerging therapies in androgen-driven disorders","volume":"23","author":"Wang","year":"2026","journal-title":"Nat. Rev. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.eururo.2011.06.020","article-title":"SRD5A polymorphisms and biochemical failure after radical prostatectomy","volume":"60","author":"Bellemare","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1038\/s41467-020-19249-z","article-title":"Structure of human steroid 5alpha-reductase 2 with the anti-androgen drug finasteride","volume":"11","author":"Xiao","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"111588","DOI":"10.1016\/j.yexcr.2019.111588","article-title":"Tumor infiltrating M2 macrophages could predict biochemical recurrence of localized prostate cancer after radical prostatectomy","volume":"384","author":"Zhang","year":"2019","journal-title":"Exp. Cell Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1186\/s12967-025-06519-x","article-title":"Macrophages in prostate cancer: Dual roles in tumor progression and immune evasion","volume":"23","author":"Liu","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Siltari, A., Syvala, H., Lou, Y.R., Gao, Y., and Murtola, T.J. (2022). Role of Lipids and Lipid Metabolism in Prostate Cancer Progression and the Tumor\u2019s Immune Environment. Cancers, 14.","DOI":"10.3390\/cancers14174293"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e008094","DOI":"10.1136\/jitc-2023-008094","article-title":"Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinoma","volume":"12","author":"Zhang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3892\/or.2014.3684","article-title":"Beneficial effect of T follicular helper cells on antibody class switching of B cells in prostate cancer","volume":"33","author":"Tan","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1158\/1940-6207.CAPR-08-0167","article-title":"Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro","volume":"2","author":"McLarty","year":"2009","journal-title":"Cancer Prev. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJMra1814259","article-title":"Machine Learning in Medicine","volume":"380","author":"Rajkomar","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","article-title":"High-performance medicine: The convergence of human and artificial intelligence","volume":"25","author":"Topol","year":"2019","journal-title":"Nat. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s42256-019-0138-9","article-title":"From Local Explanations to Global Understanding with Explainable AI for Trees","volume":"2","author":"Lundberg","year":"2020","journal-title":"Nat. Mach. Intell."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.ccell.2022.09.012","article-title":"Artificial intelligence for multimodal data integration in oncology","volume":"40","author":"Lipkova","year":"2022","journal-title":"Cancer Cell."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.bcp.2011.07.093","article-title":"Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications","volume":"82","author":"Singh","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"ref_47","first-page":"69","article-title":"EGCG suppresses prostate cancer cell growth modulating acetylation of androgen receptor by anti-histone acetyltransferase activity","volume":"30","author":"Lee","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1002\/ijc.24988","article-title":"Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells","volume":"126","author":"Pandey","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.freeradbiomed.2006.01.005","article-title":"Epigallocathechin-3 gallate inhibits cardiac hypertrophy through blocking reactive oxidative species-dependent and -independent signal pathways","volume":"40","author":"Li","year":"2006","journal-title":"Free Radic. Biol. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.1002\/ptr.7990","article-title":"Epigallocatechin gallate circumvents drug-induced resistance in non-small-cell lung cancer by modulating glucose metabolism and AMPK\/AKT\/MAPK axis","volume":"37","author":"Zhou","year":"2023","journal-title":"Phytother. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.canlet.2006.03.030","article-title":"Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway","volume":"247","author":"Hwang","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ijc.11317","article-title":"Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells","volume":"106","author":"Brusselmans","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Li, D., Cao, D., Sun, Y., Cui, Y., Zhang, Y., Jiang, J., and Cao, X. (2024). The roles of epigallocatechin gallate in the tumor microenvironment, metabolic reprogramming, and immunotherapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1331641"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/0008-5472.CAN-05-1145","article-title":"Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study","volume":"66","author":"Bettuzzi","year":"2006","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.3390\/ijms12095592","article-title":"Epigallocatechin-3-gallate (EGCG) for clinical trials: More pitfalls than promises?","volume":"12","author":"Mereles","year":"2011","journal-title":"Int. J. Mol. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00228-008-0610-7","article-title":"Hepatotoxicity from green tea: A review of the literature and two unpublished cases","volume":"65","author":"Mazzanti","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS), Younes, M., Aggett, P., Aguilar, F., Crebelli, R., Dusemund, B., Filipic, M., Frutos, M.J., Galtier, P., and Gott, D. (2018). Scientific opinion on the safety of green tea catechins. EFSA J., 16, e05239.","DOI":"10.2903\/j.efsa.2018.5239"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12943-023-01849-0","article-title":"Lipid polymer hybrid nanoparticles: A custom-tailored next-generation approach for cancer therapeutics","volume":"22","author":"Gajbhiye","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.semcancer.2016.06.003","article-title":"Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer","volume":"40\u201341","author":"Kallifatidis","year":"2016","journal-title":"Semin. Cancer Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.clnu.2013.03.008","article-title":"Green tea polyphenol epigallocatechin-3-gallate (EGCG) as adjuvant in cancer therapy","volume":"32","author":"Lecumberri","year":"2013","journal-title":"Clin. Nutr."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1442-2042.2007.01774.x","article-title":"Epigallocatechin-3-gallate and bicalutamide cause growth arrest and apoptosis in NRP-152 and NRP-154 prostate epithelial cells","volume":"14","author":"Morrissey","year":"2007","journal-title":"Int. J. Urol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/ng.3315","article-title":"Spatial genomic heterogeneity within localized, multifocal prostate cancer","volume":"47","author":"Boutros","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_63","first-page":"575","article-title":"Gene co-expression analysis for functional classification and gene-disease predictions","volume":"19","author":"Vosa","year":"2018","journal-title":"Brief. Bioinform."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrg1272","article-title":"Network biology: Understanding the cell\u2019s functional organization","volume":"5","author":"Barabasi","year":"2004","journal-title":"Nat. Rev. Genet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41467-021-27322-4","article-title":"Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states","volume":"13","author":"Song","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.eururo.2020.12.037","article-title":"Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer","volume":"79","author":"Athie","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/jnci\/djp335","article-title":"Use of archived specimens in evaluation of prognostic and predictive biomarkers","volume":"101","author":"Simon","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41556-020-00613-6","article-title":"Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression","volume":"23","author":"Chen","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/onc.2013.191","article-title":"Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression","volume":"33","author":"Comito","year":"2014","journal-title":"Oncogene"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1158\/0008-5472.CAN-13-2921-T","article-title":"High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development","volume":"74","author":"Lin","year":"2014","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Langfelder, P., and Horvath, S. (2008). WGCNA: An R package for weighted correlation network analysis. BMC Bioinform., 9.","DOI":"10.1186\/1471-2105-9-559"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1093\/bioinformatics\/btv313","article-title":"DSigDB: Drug signatures database for gene set analysis","volume":"31","author":"Yoo","year":"2015","journal-title":"Bioinformatics"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/4797\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:23:09Z","timestamp":1780546989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/4797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":74,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27114797"],"URL":"https:\/\/doi.org\/10.3390\/ijms27114797","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]}}}